Show simple item record

dc.contributor.authorHong, Ming
dc.contributor.authorShi, Honglian
dc.contributor.authorWang, Ning
dc.contributor.authorTan, Hor-Yue
dc.contributor.authorWang, Qi
dc.contributor.authorFeng, Yibin
dc.date.accessioned2020-11-18T15:27:41Z
dc.date.available2020-11-18T15:27:41Z
dc.date.issued2019-06-26
dc.identifier.citationHong, M., Shi, H., Wang, N., Tan, H. Y., Wang, Q., & Feng, Y. (2019). Dual Effects of Chinese Herbal Medicines on Angiogenesis in Cancer and Ischemic Stroke Treatments: Role of HIF-1 Network. Frontiers in pharmacology, 10, 696. https://doi.org/10.3389/fphar.2019.00696en_US
dc.identifier.urihttp://hdl.handle.net/1808/30873
dc.descriptionThis work is licensed under a Creative Commons Attribution 4.0 International License.en_US
dc.description.abstractHypoxia-inducible factor-1 (HIF-1)–induced angiogenesis has been involved in numerous pathological conditions, and it may be harmful or beneficial depending on the types of diseases. Exploration on angiogenesis has sparked hopes in providing novel therapeutic approaches on multiple diseases with high mortality rates, such as cancer and ischemic stroke. The HIF-1 pathway is considered to be a major regulator of angiogenesis. HIF-1 seems to be involved in the vascular formation process by synergistic correlations with other proangiogenic factors in cancer and cerebrovascular disease. The regulation of HIF-1–dependent angiogenesis is related to the modulation of HIF-1 bioactivity by regulating HIF-1α transcription or protein translation, HIF-1α DNA binding, HIF-1α and HIF-1α dimerization, and HIF-1 degradation. Traditional Chinese herbal medicines have a long history of clinical use in both cancer and stroke treatments in Asia. Growing evidence has demonstrated potential proangiogenic benefits of Chinese herbal medicines in ischemic stroke, whereas tumor angiogenesis could be inhibited by the active components in Chinese herbal medicines. The objective of this review is to provide comprehensive insight on the effects of Chinese herbal medicines on angiogenesis by regulating HIF-1 pathways in both cancer and ischemic stroke.en_US
dc.description.sponsorshipNational Natural Science Foundation of China (No. 81673627)en_US
dc.description.sponsorshipGuangzhou Science Technology and Innovation Commission Research Projects (201805010005)en_US
dc.description.sponsorshipResearch Grant Council, HKSAR (Project code: RGC GRF 17152116)en_US
dc.description.sponsorshipCommissioner for Innovation Technology, HKSAR (Project code: ITS/091/16FX)en_US
dc.publisherFrontiers Mediaen_US
dc.rights© 2019 Hong, Shi, Wang, Tan, Wang and Feng.en_US
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_US
dc.subjectAngiogenesisen_US
dc.subjectHerbal medicineen_US
dc.subjectHypoxia-inducible factor-1en_US
dc.subjectCanceren_US
dc.subjectIschemic strokeen_US
dc.titleDual Effects of Chinese Herbal Medicines on Angiogenesis in Cancer and Ischemic Stroke Treatments: Role of HIF-1 Networken_US
dc.typeArticleen_US
kusw.kuauthorShi, Honglian
kusw.kudepartmentPharmacology and Toxicologyen_US
dc.identifier.doi10.3389/fphar.2019.00696en_US
kusw.oaversionScholarly/refereed, publisher versionen_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US
dc.identifier.pmidPMC6606950en_US
dc.rights.accessrightsopenAccessen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2019 Hong, Shi, Wang, Tan, Wang and Feng.
Except where otherwise noted, this item's license is described as: © 2019 Hong, Shi, Wang, Tan, Wang and Feng.